Recordati (OTCMKTS:RCDTF) Earns “Hold” Rating from Zacks Investment Research

Recordati (OTCMKTS:RCDTF)‘s stock had its “hold” rating restated by Zacks Investment Research in a research report issued on Saturday, Zacks.com reports.

According to Zacks, “Recordati S.p.A. is a pharmaceutical company. It engaged in the research, development, manufacturing and marketing of pharmaceuticals for rare disease treatments. The company operates primarily in Russia, Turkey, North Africa and United States of America. Recordati S.p.A. is headquartered in Milan, Italy. “

The firm’s 50 day simple moving average is $34.70. The company has a market capitalization of $7.26 billion, a PE ratio of 19.83, a price-to-earnings-growth ratio of 3.44 and a beta of 0.05. Recordati has a one year low of $34.70 and a one year high of $34.87.

About Recordati

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals in Europe, the Middle East, Africa, the United States, Canada, and internationally. The company offers pharmaceuticals in various therapeutic areas, including cardiovascular, cosmetics, dermatology, dietary supplements, gynecology and obstetrics, medical devices, musculo-skeletal disorders and analgesia, over the counter/non-prescription pharmaceuticals, urology, allergy, anti-infectives, central nervous system, endocrinology, gastrointestinal, nutrition and related products, immune-suppressants, pain management/inflammation, generics, pneumology, antipyretics and cold preparations, endocrinology, oncology, respiratory, and radio contrast agent, as well as ear, nose, and throat.

See Also: The Discount Rate – What You Need to Know

Get a free copy of the Zacks research report on Recordati (RCDTF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Recordati Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recordati and related companies with MarketBeat.com's FREE daily email newsletter.